The US and EU have meaningfully different compliance frameworks for a leave-on body cream containing tranexamic acid and retinol, and understanding both upfront prevents expensive reformulation or market withdrawal later.
In the United States, topical cosmetics do not require pre-market FDA approval. There is no mandatory registration, though the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) requires cosmetic facilities to register with the FDA and brands to list their products in the FDA Cosmetic Product Registry beginning in 2024. You will need to maintain a complete product file that includes: the formula with all ingredient percentages, a safety assessment (not legally mandated but strongly recommended and increasingly expected by major retailers), a stability study, a Preservative Efficacy Test (USP 51 or equivalent), and a Certificate of Analysis for each production batch. If your manufacturer is FDA-registered and operates under ISO 22716 GMP, they will typically provide most of this documentation as part of their standard deliverables. Ensure your label includes a full INCI ingredient list, net weight in US customary and metric units, manufacturer or distributor name and address, and any required warnings.
For the EU, the requirements are more formal. The Cosmetic Products Regulation (EC) No 1223/2009 requires that before placing a product on the EU market, a Responsible Person (RP) — a legal entity established in the EU — must be appointed. The RP must compile and hold a Cosmetic Product Safety Report (CPSR), which consists of Part A (safety information: formula, physical and chemical properties, toxicological profile of ingredients, preservative efficacy, stability data) and Part B (safety assessment signed by a qualified safety assessor). Retinol in leave-on body products is restricted to a maximum of 0.05%; if your formula exceeds this, it cannot be placed on the EU market without reformulation. Product information must be notified in the CPNP (Cosmetics Products Notification Portal) before sale. Labels must include the INCI list, period after opening symbol, batch code, and warnings in the language(s) of the country of sale.
For both markets, avoid drug claims. Language like "treats dark spots," "reduces hyperpigmentation clinically," or "reverses photodamage" could trigger drug classification in the US (requiring NDA approval) or medicinal product classification in the EU (requiring marketing authorization). Use cosmetic claim language: "visibly brightens," "helps even skin tone," "supports skin renewal."
If you plan to sell on Amazon or in major retail chains, expect to provide Certificates of Analysis, SDS sheets, and safety assessment summaries during vendor onboarding. AJ Cosmo Labs can connect you with regulatory consultants and safety assessors through the platform who specialize in exactly this type of dual-market compliance.
Ingredients in this answer: Tranexamic Acid · Retinol
Read the full guide on Private Label Tranexamic Acid Retinol Body Cream Low MOQ →